TY - JOUR
T1 - Essential thrombocythemia in a child
T2 - Management with anagrelide
AU - Chintagumpala, Murali
AU - Steuber, C. Philip
AU - Mahoney, Donald H.
AU - Ogden, Angela K.
AU - Fernbach, Donald J.
PY - 1991/1/1
Y1 - 1991/1/1
N2 - Essential thrombocythemia (ET) is a rare disorder in children. An 11-year-old white boy was first seen in January 1986 with symptoms of abdominal pain. His platelet count was 1.5 million/mm3. Other hematological values and coagulation studies, including bleeding time, were normal. There was laboratory evidence of mild platelet dysfunction. Using the criteria of the Polycythemia Vera Study Group, a diagnosis of ET was made. He developed frequent headaches. Aspirin was prescribed for the next 2 years at varying doses and frequency. During this period, platelet counts ranged between 1 and 3 million/mm3. In view of progressive headaches and evidence of increasing platelet dysfunction, further treatment was indicated. The use of a new agent, anagrelide, reported effective in adults with ET, resulted in amelioration of symptoms and improvement in quantitative and qualitative platelet control with no significant untoward effects.
AB - Essential thrombocythemia (ET) is a rare disorder in children. An 11-year-old white boy was first seen in January 1986 with symptoms of abdominal pain. His platelet count was 1.5 million/mm3. Other hematological values and coagulation studies, including bleeding time, were normal. There was laboratory evidence of mild platelet dysfunction. Using the criteria of the Polycythemia Vera Study Group, a diagnosis of ET was made. He developed frequent headaches. Aspirin was prescribed for the next 2 years at varying doses and frequency. During this period, platelet counts ranged between 1 and 3 million/mm3. In view of progressive headaches and evidence of increasing platelet dysfunction, further treatment was indicated. The use of a new agent, anagrelide, reported effective in adults with ET, resulted in amelioration of symptoms and improvement in quantitative and qualitative platelet control with no significant untoward effects.
KW - Anagrelide
KW - Essential thrombocythemia
UR - http://www.scopus.com/inward/record.url?scp=0026023062&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026023062&partnerID=8YFLogxK
U2 - 10.1097/00043426-199121000-00013
DO - 10.1097/00043426-199121000-00013
M3 - Article
C2 - 2029080
AN - SCOPUS:0026023062
SN - 1077-4114
VL - 13
SP - 52
EP - 56
JO - Journal of pediatric hematology/oncology
JF - Journal of pediatric hematology/oncology
IS - 1
ER -